Suggested Remit - To appraise the clinical and cost-effectiveness of tagraxofusp within its marketing authorisation for treating patients with blastic plasmacytoid dendritic cell neoplasm
Status In progress
Process STA 2018
ID number 1556

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
07 October 2019 (10:00) Scoping workshop (Manchester)
16 August 2019 - 16 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress, Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance